Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera

Simple item page
dc.contributor.buuauthorKarkucak, Mutlu
dc.contributor.buuauthorYakut, Tahsin
dc.contributor.buuauthorÖzkocaman, Vildan
dc.contributor.buuauthorÖzkalemkaş, Fahir
dc.contributor.buuauthorAli, Rıdvan
dc.contributor.buuauthorBayram, Murat
dc.contributor.buuauthorGörükmez, Orhan
dc.contributor.buuauthorOcakoğlu, Gökhan
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Tıbbi Genetik Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.tr_TR
dc.contributor.researcheridAAH-1854-2021tr_TR
dc.contributor.researcheridAAH-5180-2021tr_TR
dc.contributor.researcheridAAG-8495-2021tr_TR
dc.contributor.scopusid35388323500tr_TR
dc.contributor.scopusid6602802424tr_TR
dc.contributor.scopusid6603145040tr_TR
dc.contributor.scopusid6601912387tr_TR
dc.contributor.scopusid7201813027tr_TR
dc.contributor.scopusid54419512800tr_TR
dc.contributor.scopusid56681045900tr_TR
dc.contributor.scopusid15832295800tr_TR
dc.date.accessioned2022-05-13T12:48:47Z
dc.date.available2022-05-13T12:48:47Z
dc.date.issued2012-09
dc.description.abstractAn activating mutation of Janus kinase 2 (JAK2-V617F) was previously described in chronic myeloproliferative disorders (MPD). In previously published studies, the frequency of the JAK2-V617F mutation was determined to be 80-90 % for patients with polycythemia vera (PV) and 40-70 % for essential thrombocythemia (ET). In this study, we analyzed the relationship between the JAK2-V617F mutation and clinical-hematological parameters in Turkish patients with MPD and compared these findings with published studies from other geographic regions. A total of 148 patients were studied; of which, 70 were diagnosed with PV and 78 with ET. The mutation status of JAK2 was determined using a tetra-primer polymerase chain reaction. We found that 80 % of the PV group and 42 % of the ET group were positive for the JAK2-V617F mutation. When all patients were analyzed, the levels of white blood cells, hemoglobin and splenomegaly were significantly different in patients with the JAK2-V617F mutation (p < 0.05). To our knowledge, this study is the first to evaluate the relationship between MPD and JAK2-V617F in Turkish patients. The JAK2-V617F mutation is frequently detected in the Turkish patients with MPD, and especially in patients with PV. Hence, it would be useful to include JAK2 mutation screening in the initial evaluation of patients suspected to have MPD.en_US
dc.identifier.citationKarkucak, M. vd. (2012). "Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera". Molecular Biology Reports, 39(9), 8663-8667.en_US
dc.identifier.endpage8667tr_TR
dc.identifier.issn0301-4851
dc.identifier.issn1573-4978
dc.identifier.issue9tr_TR
dc.identifier.pubmed22722988tr_TR
dc.identifier.scopus2-s2.0-84865147431tr_TR
dc.identifier.startpage8663tr_TR
dc.identifier.urihttps://doi.org/10.1007/s11033-012-1721-x
dc.identifier.urihttps://link.springer.com/article/10.1007%2Fs11033-012-1721-x
dc.identifier.urihttp://hdl.handle.net/11452/26461
dc.identifier.volume39tr_TR
dc.identifier.wos000306799700011tr_TR
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.journalMolecular Biology Reportsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBiochemistry & molecular biologyen_US
dc.subjectJak2en_US
dc.subjectEssential thrombocythemiaen_US
dc.subjectPolycythemia veraen_US
dc.subjectChronic myeloproliferative disordersen_US
dc.subjectJak2 v617f mutationen_US
dc.subjectClassificationen_US
dc.subjectTyrosine kinase jak2en_US
dc.subjectWorld-health-organizationen_US
dc.subjectNeoplasmsen_US
dc.subjectTetraen_US
dc.subject.emtreeHemoglobinen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeClinical evaluationen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeEthnic groupen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeGeneen_US
dc.subject.emtreeGene frequencyen_US
dc.subject.emtreeGene mutationen_US
dc.subject.emtreeHemoglobin blood levelen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeJak2 v617f geneen_US
dc.subject.emtreeLeukocyteen_US
dc.subject.emtreeLeukocyte counten_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreePolycythemia veraen_US
dc.subject.emtreePopulation researchen_US
dc.subject.emtreeSplenomegalyen_US
dc.subject.emtreeThrombocyte counten_US
dc.subject.emtreeThrombocythemiaen_US
dc.subject.emtreeTurkishen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshFemaleen_US
dc.subject.meshGenotypeen_US
dc.subject.meshHumansen_US
dc.subject.meshJanus kinase 2en_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshMutationen_US
dc.subject.meshMutation rateen_US
dc.subject.meshMyeloproliferative disordersen_US
dc.subject.meshPolycythemia veraen_US
dc.subject.meshThrombocythemia, essentialen_US
dc.subject.meshTurkeyen_US
dc.subject.scopusThrombocythemia; Primary Myelofibrosis; Polycythemia Veraen_US
dc.subject.wosBiochemistry & molecular biologyen_US
dc.titleEvaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia veraen_US
dc.typeArticle
dc.wos.quartileQ3en_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus